Evidence map›Paper›PMID 37937428›Full record

ArticleJournal of psychopharmacology (Oxford, England)2023

The potential for medicinal cannabis to help manage challenging behaviour in people with intellectual disability: A perspective review.

Laura Korb, Samuel Tromans, Bhathika Perera, Nagina Khan, Lisa Burrows, Richard Laugharne, Angela Hassiotis, Victoria Allgar, Daryl Efron, Ian Maidment and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 3 countries.

Laura KorbHaringey Learning Disability Partnership, Barnet Enfield and Haringey Mental Health NHS Trust, London, UK.
Samuel TromansDepartment of Population Health Sciences, University of Leicester, Leicester, UK.
Bhathika PereraNorth East London NHS Foundation Trust, London, UK.
Nagina KhanCentre for Addiction and Mental Health, Toronto, Canada.
Lisa BurrowsRoyal Cornwall Hospitals NHS Trust, Truro, UK.
Richard LaugharneCornwall Intellectual Disability Equitable Research (CIDER), University of Plymouth Peninsula School of Medicine, Truro, UK.
Angela HassiotisDivision of Psychiatry, University College London, London, UK.
Victoria AllgarPeninsula Clinical Trials Unit, Faculty of Health, University of Plymouth, Truro, UK.
Daryl EfronRoyal Children's Hospital, Melbourne, Australia.
Ian MaidmentCollege of Life and Health Sciences, Aston School of Pharmacy, Aston University, Birmingham, UK.
Rohit ShankarCornwall Intellectual Disability Equitable Research (CIDER), University of Plymouth Peninsula School of Medicine, Truro, UK.ORCID 0000-0002-1183-6933
University of Plymouth · GBAston University · GBBarnet Enfield and Haringey Mental Health Trust · GBCentre for Addiction and Mental Health · CANorth East London NHS Foundation Trust · GBRoyal Children's Hospital · AURoyal Cornwall Hospital Trust · GBUniversity College London · GBUniversity of Leicester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAround 2% of the population have intellectual disabilities. Over one-third people with intellectual disabilities (PwID) present with 'challenging behaviour', which nosologically and diagnostically is an abstract concept. Challenging behaviour is influenced by a range of bio-psycho-social factors in a population, which is unable to suitably comprehend and/or communicate concerns. This predisposes to poor health and social outcomes. There is no evidence-based treatments for managing challenging behaviour. Cannabidiol (CBD) and tetrahydrocannabinol (THC) are being trialled for a range of disorders, which are over-represented in PwID and provoke challenging behaviours, such as severe epilepsy, spasticity, post-traumatic stress disorder, social phobia, pain, etc.

methodsThis perspective review explores the different conditions, which benefit from medicinal CBD/THC preparations, by analysing recent literature from neurobiological, pre-clinical and clinical studies related to the topic. The evidence is synthesised to build an argument of the therapeutic benefits and challenges of medicinal cannabis to manage severe challenging behaviour in PwID.

resultsThere is developing evidence of medicinal CBD/THC improving psychiatric and behavioural presentations in general. In particular, there is emergent proof in certain key areas of influence of medicinal CBD/THC positively supporting challenging behaviour, for example in children with neurodevelopmental disorders. However, there are significant challenges in employing such treatments in vulnerable populations such as PwID.

conclusionFurther clinical research for the considered use of medicinal CBD/THC for challenging behaviour management in PwID is needed. Strong co-production with experts with lived experience is needed for further testing to be done in this exciting new area.

Indexed as

CannabidiolCannabisIntellectual DisabilityMedical MarijuanaSubstance Abuse, IntravenousChildDronabinolHumansCannabidiolDronabinolMedical Marijuanachallenging behaviourdevelopmental disordersintellectual disabilityMedicinal cannabispolypharmacy

Identifiers

PMID37937428
PMCPMC10714688
OpenAlexW4388493309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.